Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti–Programmed Cell Death 1 Immunotherapy

Jianying Xu(LMU Klinikum), Feng‐Hua Wang(Sun Yat-sen University), Chao Ren(Sun Yat-sen University), Yiqin Wang(Sun Yat-sen University), Jiayu Li(Shanxi Medical University), Xiaoli Wei(Anhui Medical University), Junliang Chen(Sun Yat-sen University), Yao-Fang Hu, Yang Zhang(Dalian Medical University), Fei Han(Sun Yat-sen University)
JAMA Network Open
March 1, 2022
10.1001/jamanetworkopen.2022.0587
Cited by 64

Related Papers

Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
Erythrocyte–Platelet Hybrid Membrane Coating for Enhanced Nanoparticle Functionalization
|Advanced Materials|2017|756
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
|Annals of Oncology|2019|475
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
|Journal of Clinical Oncology|2021|350